Spatial Transcriptomics · Intellectual Property · Corporate Restructuring · Bruker · Business ReportSources read 17 October 2026
Three companies, one division, one unanswered question
Bruker’s spatial biology division: NanoString, Canopy and Acuity
Bruker Spatial Biology, formed on 9 October 2024, puts three businesses under one division of Bruker’s BSI NANO segment: NanoString, bought out of Chapter 11 for $392.6 million in May 2024; Canopy Biosciences, bought in 2020; and Bruker Spatial Genomics, the renamed Acuity Spatial Genomics that Bruker founded with Harvard technology in 2021. A fourth, Bruker Cellular Analysis, joined on 1 April 2026. Between them they measure DNA folding, RNA, protein and live-cell behaviour in tissue. NanoString collapsed under a patent war with 10x Genomics and years of losses; Bruker settled that war in May 2025 for $68.0 million plus royalties. What is not known is whether the division makes money: Bruker publishes no division revenue, took goodwill impairments touching it in late 2025 and mid-2026, and its finance chief said in August 2026 that it was still losing money.
What Happened
What is established, and how firmly Each item with its standing first, read at the companies’ filings and releases.
- $392.6Mcash Bruker paid for NanoString’s business, 6 May 2024
- $68.0Msettlement with 10x Genomics, in four quarterly instalments, plus royalties on GeoMx and CosMx
- $36.5Mgoodwill impairment on the division alone, second quarter of 2026
- $174.5Mthe division’s goodwill left after that charge
| Standing | What | Read at |
|---|---|---|
| Confirmed: filing | NanoString filed for Chapter 11 in Delaware on 4 February 2024. Bruker won the auction on 16 April 2024 and closed on 6 May 2024 at $392,555,000 cash, 78.4% above the $220 million stalking-horse bid. | NanoString Form 8-Ks of 5 Feb, 19 Apr and 6 May 2024 |
| Confirmed: filing | On 17 November 2023 a Delaware jury found NanoString wilfully infringed seven 10x Genomics patents with GeoMx and awarded about $31 million. | NanoString Form 8-K, 20 Nov 2023 |
| Confirmed: filing | On 12 May 2025 Bruker and 10x settled every case in every jurisdiction: $68.0 million in four quarterly instalments from the third quarter of 2025, the last paid by 30 June 2026, plus royalties on GeoMx and CosMx sales for the life of the patents. | 10x Form 8-K, 14 May 2025; Bruker Form 10-Q, Q2 2026 |
| Confirmed: filing | Bruker bought Canopy Biosciences on 10 September 2020 for $24.2 million, with up to $5.0 million more tied to 2021 and 2022 revenue. | Bruker Form 10-Q, Q3 2020 |
| Confirmed: filing | Goodwill impairments: $96.5 million in the third quarter of 2025 across the division and an automation unit, not split; $36.5 million on the division alone in the second quarter of 2026, leaving $174.5 million. | Bruker Form 10-Qs, Q3 2025 and Q2 2026 |
| Confirmed: filing | Bruker Cellular Analysis, the former PhenomeX, was merged into the division on 1 April 2026. | Bruker Form 10-Q, Q2 2026 |
| Confirmed: company release | Bruker formed the division on 9 October 2024 from NanoString, Canopy and Bruker Spatial Genomics, the renamed Acuity, in “operational coordination”, with Todd Garland as president. | Bruker press release, 9 Oct 2024 |
| Confirmed: company release | Acuity Spatial Genomics was formed in March 2021 with a majority investment by Bruker and an exclusive Harvard licence; Bruker’s Mark Munch was its CEO. | SelectScience, 23 Mar 2021 |
| Company target, not an outcome | At the deal, Bruker said that by 2026 it expected NanoString to be “near break-even”. In August 2026 its finance chief said the spatial business “continued to experience operating losses”. | Bruker exhibit, 22 Apr 2024; Q2 2026 call transcript |
| Company expectation | Shipments of the PaintScape 3D-genome instrument were expected from the second quarter of 2026 and of CellScape XR in summer 2026; no text read confirms either. | Bruker releases, 23 Feb and 17 Apr 2026 |
| Not public | The division’s revenue and profit. Bruker reports only the BSI NANO segment, which also sells X-ray, atomic force microscopy and semiconductor metrology tools: $1,084.3 million in 2025. | Bruker Form 10-K, 2025 |
What is settled
Who owns what, what was paid for it, how the litigation ended and what the settlement costs in cash are all in filings.
What is not
Whether the division is near break-even, how large it is, and whether the 2026 instruments shipped on time.
Timeline
Twenty-three years, three companies Dated by the document that carries each item.
- Jun 2003NanoString is incorporated in Delaware, on barcode-counting technology conceived in Leroy Hood’s laboratories at the Institute for Systems Biology, Seattle; an exclusive licence follows in 2004.
- Oct 2008The first nCounter system is sold.
- 2013NanoString’s shares are approved for listing on Nasdaq as NSTG; its accumulated deficit is $102.8 million at 31 March 2013.
- Late 2016Canopy Biosciences is founded in St. Louis by the investor BioGenerator.
- 2019GeoMx Digital Spatial Profiler is launched.
- 10 Sep 2020Bruker acquires Canopy Biosciences ($24.2 million, up to $5.0 million more).
- 23 Mar 2021Acuity Spatial Genomics announces its formation and a majority investment by Bruker.
- 6 May 202110x Genomics sues NanoString in Delaware over GeoMx; a second suit, over CosMx, follows on 28 February 2022, and a Munich suit on 9 March 2022.
- 3 Mar 2022Canopy launches CellScape, the Bruker-designed next generation of its ChipCytometry instrument.
- Dec 2022CosMx Spatial Molecular Imager and the AtoMx cloud platform are launched.
- 17 May 2023The Munich Regional Court enjoins CosMx RNA products in Germany, from 1 June.
- 19 Sep 2023The Unified Patent Court’s Munich division issues a preliminary injunction on CosMx RNA products across its 17 member states.
- 2 Oct 2023Bruker completes its purchase of PhenomeX, agreed on 17 August at $1.00 a share; it is renamed Bruker Cellular Analysis.
- Oct 2023NanoString cuts about 110 positions, about 20% of its workforce.
- 17 Nov 2023Delaware jury verdict against GeoMx, about $31 million; on 19 November NanoString withdraws its 2023 guidance.
- 31 Dec 2023A second cut: about 50 positions, about 9%.
- 4 Feb 2024NanoString files for Chapter 11; Nasdaq suspends trading in its shares on 14 February.
- 26 Feb 2024The UPC Court of Appeal lifts the preliminary injunction; CosMx sales resume in 16 countries.
- 16 Apr 2024Bruker wins the auction against a $220 million stalking-horse bid; the court approves on 19 April.
- 6 May 2024The sale closes at $392,555,000; Bruker takes on $44.7 million of litigation liability.
- 9 Oct 2024Bruker Spatial Biology is formed.
- 23 Dec 202410x announces a US permanent injunction against GeoMx, sparing customers who installed before 18 November 2023.
- 21 Feb 2025At AGBT 2025: a CosMx whole-transcriptome panel (over 18,000 RNA transcripts) and PaintScape for the 3D genome.
- 12 May 2025Global settlement with 10x: $68.0 million plus royalties.
- Aug 2025Bruker announces $100–120 million of annual cost savings for 2026, later raised to $140 million.
- Q3 2025$96.5 million goodwill impairment across the division and an automation unit.
- 23 Feb 2026At AGBT 2026: CellScape XR, a mouse whole-transcriptome assay, PaintScape pre-orders, and a Glasgow centre of excellence.
- 1 Apr 2026Bruker Cellular Analysis merges into the division.
- Apr 202610x announces Atera, a whole-transcriptome in situ platform; at AACR on 17 April, Bruker shows workflows linking GeoMx, CellScape XR and CosMx on one section.
- Q2 2026$36.5 million impairment on the division; the last settlement instalment is paid.
- 1 Jul 2026Bruker reorganises into four groups; the BSI NANO segment, home of the division, is unchanged.
- Sep 202610x begins commercial shipments of Atera, with more than 40 instruments booked.
What cannot be dated. Whether PaintScape, CellScape XR and the mouse whole-transcriptome assay shipped when Bruker expected; whether the NanoString business came “near break-even” in 2026; how the $96.5 million charge of late 2025 divided between the division and the automation unit; and when Bruker will report its third quarter of 2026. None of the documents read settles any of them.
The Argument
A sound technology business that could not pay for its own war What the filings show, what Bruker argues, and where the two meet.
Losses
Revenue grew; the losses never closed
- 2022: revenue $127.3 million, net loss $159.5 million.
- Nine months of 2023: revenue $128.1 million, net loss $122.3 million; about $168 million for the full year, by Bruker’s count.
- Accumulated deficit at 30 September 2023: $931.6 million.
Litigation
Four years, three court systems
- Injunctions in Germany (May 2023) and across the Unified Patent Court states (September 2023) hit CosMx.
- The November 2023 jury verdict on GeoMx came with a guidance withdrawal two days later.
- Bruker inherited the cases and settled them in May 2025.
Assembly
Three routes into one division
- Canopy: an acquisition, in 2020.
- Acuity: a venture Bruker formed itself, in 2021.
- NanoString: a bankruptcy purchase, in 2024.
Bruker’s case. When it bought NanoString, Bruker said it expected the business “to have rebounded and to be near break-even” by 2026, helped by not taking on NanoString’s public-company overhead, and the combined spatial business to grow at double-digit organic rates from 2027. Mark Munch, president of the Bruker NANO group, argued in October 2024 for “fit-for-purpose” platforms kept apart, each with its own team: “The road to failure, and the road to mediocrity, is to try to make a Swiss Army knife.” When 10x launched Atera in 2026, chief executive Frank Laukien said it was “remarkable to read that someone invented what we did a year ago”. These are a buyer’s and a competitor’s claims. The settlement is not a claim: 10x booked $40.7 million of the $68.0 million as a gain and $27.3 million as licence revenue, and the royalties on GeoMx and CosMx continue for the life of the patents.
- $40.7Mof the settlement booked by 10x as a gain
- $27.3Mbooked by 10x as licence and royalty revenue
A reading
Reading. NanoString did not fail for want of products: its revenue rose every year shown. It failed because the losses never closed while a patent war it was losing ran in three court systems at once; the verdict and the withdrawn guidance came eleven weeks before the bankruptcy. Bruker bought the products without the overhead and the war, and the price of ending the war is a royalty on two of the three spatial platforms for as long as the patents run.
What Others Add
What the division sells, and what the numbers can and cannot say Specifications are the maker’s; figures are from filings unless marked.
| Platform | From | What it measures | Scale |
|---|---|---|---|
| CosMx SMI | NanoString | RNA and protein in tissue: a human panel of over 18,000 transcripts plus 64+ proteins on one section; a mouse panel announced for 2026 | single cell, subcellular |
| GeoMx DSP | NanoString | whole transcriptome and more than 1,200 protein targets in regions the researcher selects | regions of tissue |
| nCounter | NanoString | gene expression by direct barcode counting, up to 800 genes per run | bulk sample |
| CellScape XR | Canopy | protein, by repeated staining; a 208-plex dataset across 12 human tissues shown in 2026 | subcellular |
| PaintScape | Acuity | how chromosomes fold in the nucleus: a 419-plex panel; a 1000+-plex cancer panel promised for later in 2026 | single nucleus, 3D |
| Beacon | PhenomeX | what live cells do; paired with CosMx in a 2026 head and neck cancer study | single live cell |
| AtoMx SIP | NanoString | cloud analysis for CosMx: 3D AI cell segmentation, exports for large language models | software |
Where the pieces came from. Canopy reached CellScape through a German subsidiary, Zellkraftwerk, whose ChipCytometry instrument had been in use since 2016; Canopy’s 2022 launch release calls CellScape the next generation of it, designed with Bruker’s microscopy expertise. Munch describes Canopy as having had no instrument when Bruker bought it; the two Bruker accounts differ, and the earlier instrument is on record. Acuity licensed Oligopaint-based methods from Ting Wu’s laboratory at Harvard Medical School, published in Nature Methods in 2020; two of her postdoctoral researchers, Huy Q. Nguyen and Shyamtanu Chattoraj, were cofounders. PhenomeX, itself a 2023 merger of two single-cell companies, cost Bruker $109.4 million net of cash and was booked at a $144.1 million bargain-purchase gain; in December 2025 Bruker settled a patent dispute over Beacon with an antibody-discovery company for $36.0 million plus royalties. In February 2026 Bruker announced a centre of excellence at the University of Glasgow that is to image more than 1,000 pancreatic cancer samples on CellScape, CosMx and GeoMx. For the software that reads CosMx and GeoMx data, see six single-cell analysis platforms, compared.
| Figure | Value | Read at |
|---|---|---|
| Bruker revenue, 2025 | $3.44 billion; organically −3.7% | Results release, 12 Feb 2026 |
| BSI NANO segment, 2025 | $1,084.3 million; 31.6% of Bruker | Form 10-K, 2025 |
| BSI NANO segment, first half 2026 | about $507 million; low single-digit decline | Q2 2026 call |
| Bruker revenue, Q2 2026 | $838.5 million; organically +2.8% | Results release, 4 Aug 2026 |
| Bruker guidance, 2026 | $3.54–3.57 billion; organically +1–2% | Results release, 4 Aug 2026 |
| Bruker revenue from China, first half 2026 | $178.9 million, against $215.9 million (−17.1%) | Form 10-Q, Q2 2026 |
| Cost savings, 2026 | $140 million annualised; $30 million in Q2 | Q2 2026 call |
| 10x Genomics revenue, 2025 | $642.8 million, of which $46.1 million licence and royalty | 10x Form 10-K, 2025 |
| Spatial biology market, forecast | ~$1.14 billion in 2026; ~17% a year to ~$2.46 billion in 2031 | DeciBio report page, 2025 |
The competition. 10x Genomics, the other party to the litigation, reported $642.8 million of revenue in 2025, $301.9 million in the first half of 2026. It announced Atera, a whole-transcriptome in situ platform, in April 2026, and an investment-research summary reported shipments under way by late September with more than 40 instruments booked. Munch said in 2024 that CosMx “has always led in plex”; Laukien said in 2026 that Bruker is “still very much ahead”. No independent head-to-head comparison was read for this piece, so neither claim is tested here. GEN’s 2026 ranking puts three other public companies and several private ones in the field; the largest private competitor has raised more than $300 million, and another public company’s spatial segment, at $336.4 million for its last fiscal year, is subject to an announced $11.3 billion takeover. Funding is the pressure on all of them: GEN reports about $783 million of NIH grants cut, and Bruker says US academic demand stayed soft in the second quarter of 2026 while biopharma bookings across the company rose more than 20%.
The $1.084 billion is the segment
The figure ranked first in GEN’s 2026 list is BSI NANO’s whole revenue, and GEN labels it so. That segment also sells X-ray, atomic force microscopy and semiconductor metrology tools, and Bruker discloses nothing for the spatial division within it.
Specifications are the maker’s
“Best-in-class”, “first and only” and “highest fidelity” are Bruker’s words in its own releases. Plex counts and transcript numbers are what the panels are designed to detect, not independent measurements.
Conclusion
The broadest kit in the field, and no proof yet that it pays What follows from the record, and what to watch.
What the record supports
Reading. The division’s breadth is real and documented: DNA folding, region-level and single-cell RNA, protein and live-cell function, from one owner, with workflows that pass one tissue section between instruments. The settlement removed the legal risk to buyers of GeoMx and CosMx, at the cost of a lasting royalty.
What it does not
Reading. Nothing public shows the division making money. The only evidence on profitability is two impairments nine months apart and a finance chief’s August 2026 statement of continuing operating losses, and both point the same way. Bruker’s April 2024 target, “near break-even” by 2026, has not been reported met or missed.
- Reading. For a laboratory choosing an instrument: the patent risk around GeoMx and CosMx ended with the 2025 settlement. Run the same tissue on the platforms being considered, since no independent comparison of CosMx and Atera was found, and ask for written commitments on consumables and cloud software, which depend on the division continuing in its present form.
- Reading. For anyone sizing the business: do not use the $1.084 billion; it is the whole segment. The division-level evidence is the goodwill note in each Bruker 10-Q, which says what the division is worth on Bruker’s own books.
- What to watch: Bruker’s third-quarter and full-year 2026 reports, for any further impairment and any word on break-even; whether PaintScape, CellScape XR and the mouse whole-transcriptome assay are reported shipping; and the first published comparisons of Atera and CosMx on the same tissue.
Hold loosely
Shipment dates are expectations; the break-even target is a target; the market forecast is one research seller’s, on its own definition; and Bruker’s and 10x’s claims about each other are competitors’ claims. Figures stand as they did on 17 October 2026.
Quick notes
- Bruker, press releases of 11 Sep 2020 and 9 Oct 2024
- Canopy Biosciences, release of 3 Mar 2022
- BioSTL on the Canopy acquisition
- Bruker, Forms 10-Q for Q3 2020, Q3 2025 and Q2 2026, Form 10-K for 2025, and results releases of 12 Feb, 6 May and 4 Aug 2026, SEC EDGAR
- Bruker, exhibit of 22 Apr 2024 on the NanoString deal and the PhenomeX agreement of 17 Aug 2023, SEC EDGAR
- Bruker Spatial Biology, AGBT releases of 21 Feb 2025 and 23 Feb 2026 and AACR release of 17 Apr 2026 (Business Wire, via Yahoo Finance)
- Bruker Cellular Analysis, blog of 6 Feb 2026
- NanoString, Form S-1/A (2013), Forms 10-Q for Q1 and Q3 2023, Forms 8-K of 20 Nov 2023, 5 Jan, 5 Feb, 19 Apr and 6 May 2024, SEC EDGAR
- NanoString, results release of 28 Feb 2023 and UPC appeal release of 26 Feb 2024
- 10x Genomics, Form 8-K of 14 May 2025, Forms 10-Q for Q1 2024 and Q3 2025 and Form 10-K for 2025, SEC EDGAR
- 10x Genomics, release of 23 Dec 2024 (PR Newswire) and the Atera release of Apr 2026
- SelectScience, 23 Mar 2021
- GEN, 11 Oct 2024 and 9 Oct 2026
- The Motley Fool, transcripts of Bruker’s Q1 and Q2 2026 calls
- Zacks Equity Research, 30 Sep 2026 (via Yahoo Finance)
- DeciBio, spatial biology market report page. Read 17 October 2026.
Reliable
Worth believing
Sharing a subject
- The Franchise Its Maker Did Not OwnIntellectual Property
- Same Shock, Two Balance SheetsCorporate Restructuring
- Six single-cell analysis platforms, comparedSpatial Transcriptomics
Sharing a source domain
- Six single-cell analysis platforms, compared10xgenomics.com · brukerspatialbiology.com · prnewswire.com · sec.gov
- Z.ai's Chinese-Chip Claim for GLM-5.3-Flashprnewswire.com · yahoo.com
- A Chain of Its Own, and the Bill It Still Payssec.gov · yahoo.com
- Lynas Rare Earths — Malaysian Expansion Analysisfool.com
- Jingye vs Britain — British Steel Compensation Claimprnewswire.com
- High Bandwidth Flash Gets Its First Standardprnewswire.com
- The Longer the Name, the Bigger the Thing Being Soldprnewswire.com
- How Long Can Iran Keep Fighting?yahoo.com
- Same Shock, Two Balance Sheetssec.gov
- Signed in Pencilyahoo.com
- AWS Adds 2 Million More Nvidia GPUsfool.com
- Nvidia's Record $96.2 Billion Quartersec.gov
- Is This Already a World War? Two Answers, and the Recordyahoo.com
- Four Indices, Read on One Day — and One of Them Is Twelve Years Behindyahoo.com
- Decades Rather Than Yearsyahoo.com
- Three Legal Systems: Malaysia, Singapore and Taiwanyahoo.com